UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month ended February 2024
Commission File No. 001-41493
Lichen
China Limited
(Translation of registrant’s name into English)
15th Floor, Xingang Square, Hubin North Road,
Siming District, Xiamen City,
Fujian Province, China, 361013
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form
40-F ☐
On February 26, 2024, the Board of Directors,
Nominating Committee and the Compensation Committee approved by resolution and confirmed the appointment of Mr. Robert Bodenstein as a
director of the Company, with an annual compensation of US$5,000, effective upon approval of the resolution, until
his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Bodenstein
is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Bodenstein
will be serving on the Board of Directors as a non-employee, independent director. Mr. Bodenstein has also been named as
a member of the Nominating Committee, the Compensation Committee, and the Audit Committee.
The foregoing descriptions of our offer letter
to Mr. Bodenstein is qualified in their entirety by reference to the full text thereof, which is attached as Exhibits 10.1 hereto
and incorporated by reference herein.
There are no family relationships between Mr.
Bodenstein and any other employees of the Company or members of the Board of Directors.
The biographical information of Mr. Bodenstein
is set forth below:
Robert Bodenstein,
age 61
Mr. Robert Bodenstein has over 40 years of experience
in business consulting and marketing consulting, specializing in providing management consulting services, developing business development
strategies, business evaluation, and information technology (IT) and strategic management of sustainability. He was the co-founder in
two IT start-ups and has served as a member of the board in various funding organizations. Besides, he has delivered projects in Europe,
Middle East, and Asia. He has previously worked with clients in different industries such as tourism, trade, and IT, and international
companies of different sizes.
More notably, Mr. Bodenstein has held positions
in multiple professional organizations, including serving as the Chair (2021-Present) and Vice Chair (2014-2021) of the International
Council of Management Consulting Institutes (ICMCI), as the Chair of the Chamber of Commerce Austria Consulting and Information Division,
an organization that covers management consulting, IT, and communication business, and also as the Chair of the committee under the ISO
TC 280 (Management Consultancy), which works with member countries in setting up the standard ISO 20700:2017 Management Consulting Services.
In addition, Mr. Bodenstein has co-authored several books on management consulting, including “Consulting Governance” (ISBN:
978-3-662-67945-6) and “Managing Sustainability–a strategic approach” (forthcoming spring 2024). Mr. Bodenstein
is an expert witness confirmed by oath at the Commercial Court Vienna, which also demonstrates his professional expertise in business
valuation and management.
Mr. Bodenstein received his MBA Degree in
General Management from the Joseph-Schumpeter Institut Wels, School of Applied Studies. He is a Certified Management Consultant (CMC).
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Lichen China Limited |
|
|
|
Date: February 27, 2024 |
By: |
/s/ Ya Li |
|
Name: |
Ya Li |
|
Title |
Chief Executive Officer |
2
Exhibit 10.1
Lichen China Limited
15th Floor, Xingang Square, Hubin North Road,
Siming District, Xiamen City,
Fujian Province, China, 361013
February 26, 2024
Re: Director Offer Letter – Robert Bodenstein
Dear Robert Bodenstein:
Lichen China
Limited, a Cayman Islands limited liability company (the “Company” or “we”), is pleased to offer you a position
as a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward
to your participation as a Director in the Company. Should you choose to accept this position as a Director, this letter agreement (the
“Agreement”) shall constitute an agreement between you and the Company and contains all the terms and conditions relating
to the services you agree to provide to the Company. Your appointment shall begin upon Nasdaq’s approval of Company’s listing.
1. Term.
This Agreement is effective as of the date of this Agreement. Your term as a Director shall continue subject to the provisions in
Section 9 below or until your successor is duly elected and qualified. The position shall be up for re-appointment every year by the board
of the Directors of the Company (the “Board”) and upon re-appointment, the terms and provisions of this Agreement shall remain
in full force and effect.
2. Services.
You shall render customary services as a Director, member of the Audit Committee, Nomination Committee and Compensation Committee (hereinafter,
your “Duties”). During the term of this Agreement, you may attend and participate at each meeting regarding the business and
operation issues of the Company as regularly or specially called, via teleconference, video conference or in person. You shall consult
with the members of the Board and committee (if any) regularly and as necessary via telephone, electronic mail or other forms of correspondence.
3. Services
for Others. You shall be free to represent or perform services for other persons during the term of this Agreement.
4. Compensation.
As compensation for your services to the Company, you will receive upon execution of this Agreement a compensation of $5,000 for each
calendar year of service under this Agreement on a pro-rated basis, payable every twelve months.
You shall be reimbursed
for reasonable expenses incurred by you in connection with the performance of your Duties (including travel expenses for in-person meetings).
5. D&O
Insurance Policy. During the term under this Agreement, the Company shall include you as an insured under its officers and directors
insurance policy, if available.
6. No
Assignment. Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned by you without
the prior written consent of the Company.
7. Confidential
Information; Non-Disclosure. In consideration of your access to certain Confidential Information (as defined below) of the Company,
in connection with your business relationship with the Company, you hereby represent and agree as follows:
a. Definition. For
purposes of this Agreement the term “Confidential Information” means: (i) any information which the Company possesses
that has been created, discovered or developed by or for the Company, and which has or could have commercial value or utility in the
business in which the Company is engaged; (ii) any information which is related to the business of the Company and is generally not
known by non-Company personnel; and (iii) Confidential Information includes, without limitation, trade secrets and any information
concerning products, processes, formulas, designs, inventions (whether or not patentable or registrable under copyright or similar
laws, and whether or not reduced to practice), discoveries, concepts, ideas, improvements, techniques, methods, research,
development and test results, specifications, data, know-how, software, formats, marketing plans, and analyses, business plans and
analyses, strategies, forecasts, customer and supplier identities, characteristics and agreements.
b. Exclusions.
Notwithstanding the foregoing, the term Confidential Information shall not include: (i) any information which becomes generally
available or is readily available to the public other than as a result of a breach of the confidentiality portions of this
Agreement, or any other agreement requiring confidentiality between the Company and you; (ii) information received from a third
party in rightful possession of such information who is not restricted from disclosing such information; (iii) information known by
you prior to receipt of such information from the Company, which prior knowledge can be documented and (iv) information you are
required to disclose pursuant to any applicable law, regulation, judicial or administrative order or decree, or request by other
regulatory organization having authority pursuant to the law; provided, however, that you shall first have given prior written
notice to the Company and made a reasonable effort to obtain a protective order requiring that the Confidential Information not be
disclosed.
c. Documents.
You agree that, without the express written consent of the Company, you will not remove from the Company’s premises, any notes,
formulas, programs, data, records, machines or any other documents or items which in any manner contain or constitute Confidential Information,
nor will you make reproductions or copies of same. You shall promptly return any such documents or items, along with any reproductions
or copies to the Company upon the Company’s demand, upon termination of this Agreement, or upon your termination or Resignation
(as defined in Section 9 herein).
d. Confidentiality.
You agree that you will hold in trust and confidence all Confidential Information and will not disclose to others, directly or indirectly,
any Confidential Information or anything relating to such information without the prior written consent of the Company, except as may
be necessary in the course of your business relationship with the Company. You further agree that you will not use any Confidential Information
without the prior written consent of the Company, except as may be necessary in the course of your business relationship with the Company,
and that the provisions of this paragraph (d) shall survive termination of this Agreement. Notwithstanding the foregoing, you may disclose
Confidential Information to your legal counsel and accounting advisors who have a need to know such information for accounting or tax
purposes and who agree to be bound by the provisions of this paragraph (d).
e. Ownership.
You agree that the Company shall own all right, title and interest (including patent rights, copyrights, trade secret rights, mask
work rights, trademark rights, and all other intellectual and industrial property rights of any sort throughout the world) relating to
any and all inventions (whether or not patentable), works of authorship, mask works, designations, designs, know-how, ideas and information
made or conceived or reduced to practice, in whole or in part, by you during the term of this Agreement and that arise out of your Duties
(collectively, “Inventions”) and you will promptly disclose and provide all Inventions to the Company. You agree to
assist the Company, at its expense, to further evidence, record and perfect such assignments, and to perfect, obtain, maintain, enforce,
and defend any rights assigned.
8. Non-Solicitation.
During the term of your appointment, you shall not solicit for employment any employee of the Company with whom you have had contact
due to your appointment.
9. Termination
and Resignation. Your services as a Director may be terminated for any or no reason by the determination of the Board. You may
also terminate your services as a Director for any or no reason by delivering your written notice of resignation to the Company (“Resignation”),
and such Resignation shall be effective upon the time specified therein or, if no time is specified, upon receipt of the notice of resignation
by the Company. Upon the effective date of the termination or Resignation, your right to compensation hereunder will terminate subject
to the Company’s obligations to pay you any compensation that you have already earned and to reimburse you for approved expenses
already incurred in connection with your performance of your Duties as of the effective date of such termination or Resignation.
10. Governing
Law; Arbitration. All questions with respect to the construction and/or enforcement of this Agreement, and the rights and
obligations of the parties hereunder, shall be determined in accordance with the law of the State of New York. All disputes with
respect to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof or any
dispute regarding non-contractual obligations arising out of or relating to it shall be referred to and finally resolved by
arbitration administered by the American Arbitration Association at its New York office in force when the Notice of Arbitration is
submitted. The law of this arbitration clause shall be New York law. The seat of arbitration shall be in New York. The number of
arbitrators shall be one. The arbitration proceedings shall be conducted in English.
11. Entire
Agreement; Amendment; Waiver; Counterparts. This Agreement expresses the entire understanding with respect to the subject matter
hereof and supersedes and terminates any prior oral or written agreements with respect to the subject matter hereof. Any term of this
Agreement may be amended and observance of any term of this Agreement may be waived only with the written consent of the parties hereto.
Waiver of any term or condition of this Agreement by any party shall not be construed as a waiver of any subsequent breach or failure
of the same term or condition or waiver of any other term or condition of this Agreement. The failure of any party at any time to require
performance by any other party of any provision of this Agreement shall not affect the right of any such party to require future performance
of such provision or any other provision of this Agreement. This Agreement may be executed in separate counterparts each of which will
be an original and all of which taken together will constitute one and the same agreement, and may be executed using facsimiles of signatures,
and a facsimile of a signature shall be deemed to be the same, and equally enforceable, as an original of such signature.
12. Indemnification.
The Company shall, to the maximum extent provided under applicable law, indemnify and hold you harmless from and against any expenses,
including reasonable attorney’s fees, judgments, fines, settlements and other legally permissible amounts (“Losses”),
incurred in connection with any proceeding arising out of, or related to, your performance of your Duties, other than any such Losses
incurred as a result of your gross negligence or willful misconduct. The Company shall advance to you any expenses, including reasonable
attorneys’ fees and costs of settlement, incurred in defending any such proceeding to the maximum extent permitted by applicable
law. Such costs and expenses incurred by you in defense of any such proceeding shall be paid by the Company in advance of the final disposition
of such proceeding promptly upon receipt by the Company of (a) written request for payment; (b) appropriate documentation evidencing the
incurrence, amount and nature of the costs and expenses for which payment is being sought; and (c) an undertaking adequate under applicable
law made by or on your behalf to repay the amounts so advanced if it shall ultimately be determined pursuant to any non- appealable judgment
or settlement that you are not entitled to be indemnified by the Company.
13. Acknowledgement. You
accept this Agreement subject to all the terms and provisions of this Agreement. You agree to accept as binding, conclusive, and
final all decisions or interpretations of the Board of Directors of the Company of any questions arising under this Agreement.
The Agreement has been
executed and delivered by the undersigned and is made effective as of the date set first set forth above.
|
Sincerely, |
|
|
|
|
Lichen China Limited |
|
|
|
|
By: |
/s/ Ya Li |
|
|
Ya Li |
|
|
Chief Executive Officer and Chairman |
AGREED AND ACCEPTED: |
|
|
|
/s/ Robert Bodenstein |
|
Robert Bodenstein |
|
Address: |
|
|
|
Phone Number: |
|
Email: |
|
4
Lichen China (NASDAQ:LICN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Lichen China (NASDAQ:LICN)
Historical Stock Chart
From Oct 2023 to Oct 2024